Last updated on September 2018

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

Brief description of study

Primary Objective:

To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment

Detailed Study Description

Secondary Objective(s):

  1. Describe persistence of ALT (alanine aminotransferase) normalization and/or improvement of ALT levels with TAF as with previous anti-HBV treatment
  2. To describe trends in serum creatinine and calculated creatinine clearance as available by local labs.
  3. To describe trends in bone mass from baseline to 24 months after switch.

Clinical Study Identifier: NCT03471624

Find a site near you

Start Over